DataJoint, a company known for its advanced computational database and AI platform, has just closed a $4.9 million Seed funding round. The round was co-led by Nina Capital from Barcelona, Inoca Capital Partners from Salt Lake City, and Capital Factory from Austin, with additional support from existing investors.
The diversity of these backers highlights the global interest in DataJoint’s technology and its potential to serve international markets.
This investment marks a significant milestone in its mission to enhance the management and analysis of research data in fields such as neuroscience, oncology, and systems biology.
With this new funding, DataJoint plans to expand its team, enhance its software-as-a-service platform, and increase its customer base in the commercial life sciences and pharmaceutical sectors, particularly in the U.S. and Europe. The company’s platform stands out because it can organize and integrate different types of research data while supporting complex AI and machine learning workflows.
This helps scientists and researchers overcome common problems, such as inconsistent data formats, poor reproducibility, and limited collaboration across laboratories.
DataJoint’s recent selection for PharmStars, a global accelerator focused on digital health startups working with pharmaceutical companies, adds another layer of momentum. Through this program, DataJoint will connect with pharma leaders to explore new partnerships and ways to apply its platform to real-world challenges in drug development and biomedical research.
The company’s origin story is rooted in the experience of its CTO, Dimitri Yatsenko. Originally from Ukraine, Dimitri studied computer science in the U.S. and began his career working on databases for public safety and later at a dot-com startup. His time at GE Medical Systems, where he led surgical imaging projects, taught him the importance of precision and quality in engineering.
After joining Ripple Neuro, a neuroscience startup, Dimitri pursued a PhD at Baylor College of Medicine and co-founded nView Medical, an AI and medical imaging company. It was during this period that he identified a significant gap in how research data was handled and how AI models were developed. That insight led him to create DataJoint, combining his engineering background with a deep understanding of scientific research.
Today, DataJoint’s platform is used by more than 100 research labs across the U.S. and Europe, including prestigious institutions like Johns Hopkins, UCSF, Harvard, and University College London.
The platform helps automate the way data is structured, processed, and analyzed, making it easier for researchers to collaborate and produce reliable results. While the company is expanding into the pharmaceutical industry, it remains committed to supporting academic medical centers, where its technology was first developed and tested.
How the funding will be used: This funding round not only gives DataJoint the resources to grow but also validates its approach to solving some of the most persistent problems in scientific research. By bridging the gap between engineering and life sciences, DataJoint enables researchers to unlock the full potential of their data.
KEY QUOTES:
“This investment will allow us to expand our reach and continue delivering transformative solutions to researchers and organizations in life sciences. With the support of Nina Capital, Inoca Capital, and Capital Factory, we are well-positioned to scale our platform and bring the power of advanced AI and data harmonization to a broader market.”
Jim Olson, CEO of DataJoint
“DataJoint’s computational database is a game-changing solution for data management and AI enablement in life sciences. Its ability to streamline workflows and improve reproducibility makes it a crucial tool for advancing scientific discovery and innovation. We are thrilled to support the team in their mission to transform research and accelerate progress in healthcare.”
Marta G. Zanchi, Founding Partner at Nina Capital
“DataJoint’s platform is uniquely positioned to address the significant challenges faced by commercial life science and pharmaceutical companies. From managing vast amounts of complex data to enabling actionable insights through AI, the opportunities for adoption in these industries are immense. We are excited to partner with DataJoint as they scale their transformative technology.”
Chris Sheffert, Managing Director at Inoca Capital
